NCT03976050: Phase I Study of HL-085 in Patients With Advanced Solid Tumors

NCT03976050
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Serine-Threonine Kinase Inhibitor, Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with active central nervous system lesions; Patients with prior therapy of an MEK inhibitor
https://ClinicalTrials.gov/show/NCT03976050

Comments are closed.

Up ↑